The NIHR-funded study, published in the medical journal Cancer Epidemiology, Biomarkers and Prevention, is the first study of its kind to develop a prostate cancer 'dietary index' which consists of dietary components - selenium, calcium and foods rich in lycopene - that have been linked to prostate cancer.
Men who had optimal intake of these three dietary components had a lower risk of prostate cancer.
Tomatoes and its products - such as tomato juice and baked beans - were shown to be most beneficial, with an 18 per cent reduction in risk found in men eating over 10 portions a week.
This is thought to be due to lycopene, an antioxidant which fights off toxins that can cause DNA and cell damage. Vanessa Er, from the School of Social and Community Medicine at the University of Bristol and Bristol Nutrition BRU, led the research.
She said: "Our findings suggest that tomatoes may be important in prostate cancer prevention. However, further studies need to be conducted to confirm our findings, especially through human trials. Men should still eat a wide variety of fruits and vegetables, maintain a healthy weight and stay active."
The researchers also looked at the recommendations on physical activity, diet and body weight for cancer prevention published by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR).
Only the recommendation on plant foods - high intake of fruits, vegetables and dietary fibre - was found to be associated with a reduced risk of prostate cancer. As these recommendations are not targeted at prostate cancer prevention, researchers concluded that adhering to these recommendations is not sufficient and that additional dietary recommendations should be developed.
The research was carried out at the National Institute for Health Research Bristol Nutrition Biomedical Research Unit in Nutrition, Diet and Lifestyle at University Hospitals Bristol NHS Foundation Trust and the University of Bristol (NIHR Bristol Nutrition BRU). The research was carried out as part of the ProtecT study, which is funded by the NIHR Health Technology Assessment programme.